StockData

Aehr Test Systems vs Data I/O

AEHR and DAIO side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AEHR and DAIO compare

Aehr Test Systems is the larger company, worth 83 times as much as Data I/O ($2.1B against $25.8M).

Aehr Test Systems grew revenue faster over the last twelve months (−15.2% versus −21.8% for Data I/O).

Aehr Test Systems keeps more of each dollar of sales as profit, with a net margin of −14.3% compared with −50.1% at Data I/O.

Data I/O scores higher on the StockData Score (8 against 6 for Aehr Test Systems), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAEHRDAIO
Size and price
Market cap$2.1B$25.8M
Share price$65.78$2.48
Change, 1 year168%−13.3%
Change, 5 years236%−49.1%
Beta (5Y)2.530.85
Employees13897
StockData Score
Total score68 (better)
Valuation score03 (better)
Growth score00
Performance score00
Health score6 (better)5
Dividend score00
Valuation
P/S42.9×1.5× (better)
P/B9.7×2.2× (better)
FCF yield−0.25% (better)−29.5%
Fair value$22.67$3.67
Margin of safety−190%32.4% (better)
Growth
Revenue growth (TTM)−15.2% (better)−21.8%
Revenue growth, 5Y average24.7% (better)1.1%
Profitability
Gross margin35.3%50.6% (better)
Operating margin−28.3% (better)−43.7%
Net margin−14.3% (better)−50.1%
FCF margin−10.8% (better)−42.8%
Return on equity−4.1% (better)−61.2%
Return on invested capital−10.4% (better)−148%
Financial health
Debt / equity0.000.00
Current ratio7.15 (better)1.93
Altman Z-score35.76 (better)0.52
Piotroski F-score33
Dividends and buybacks
Buyback yield−0.10%0.05% (better)
Shareholder yield−0.10%0.05% (better)
Ownership
Held by institutions71.3%29.9%
Held by insiders5.0%19.9%
Insider net buying, 12 months−$63.1M$1000K (better)
Short interest, % of float16.9%0.14%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.